Related Experiment Video
Updated: Apr 24, 2026
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
A phase I trial shows the drug ABT-199 effectively treats chronic lymphocytic leukemia (CLL) in patients resistant to other therapies. This novel drug targets B-cell lymphoma 2 (Bcl-2) to induce cancer cell death, with notable remission rates observed.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
- Relapsed or refractory CLL presents significant treatment challenges.
- Targeting anti-apoptotic proteins like Bcl-2 offers a therapeutic strategy.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018